Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
902
-1.34%
|
$265,188
$294.33 P/Share
|
|
Feb 10
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,461
-5.04%
|
$1,017,534
$294.33 P/Share
|
|
Feb 10
2023
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,372
-3.5%
|
$991,368
$294.33 P/Share
|
|
Feb 10
2023
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,707
-3.47%
|
$795,858
$294.33 P/Share
|
|
Feb 10
2023
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,372
-2.13%
|
$991,368
$294.33 P/Share
|
|
Feb 06
2023
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,304
-0.31%
|
$396,416
$304.48 P/Share
|
|
Feb 06
2023
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,304
+1.83%
|
$243,848
$187.53 P/Share
|
|
Feb 02
2023
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
3,578
-4.53%
|
$1,134,226
$317.83 P/Share
|
|
Feb 01
2023
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
24,322
+11.58%
|
-
|
|
Feb 01
2023
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,026
+13.88%
|
-
|
|
Feb 01
2023
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
26,400
+11.06%
|
-
|
|
Feb 01
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
BUY
Grant, award, or other acquisition
|
Direct |
29,272
+14.61%
|
-
|
|
Feb 01
2023
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
76,578
+31.09%
|
-
|
|
Feb 01
2023
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
28,452
+12.22%
|
-
|
|
Feb 01
2023
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
68,478
+14.53%
|
-
|
|
Feb 01
2023
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,293
+35.2%
|
-
|
|
Feb 01
2023
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,516
+27.2%
|
-
|
|
Feb 01
2023
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
38,221
+13.35%
|
-
|
|
Feb 01
2023
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,568
+15.83%
|
-
|
|
Jan 31
2023
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
1,200
-2.83%
|
$390,000
$325.01 P/Share
|
|
Jan 31
2023
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,200
+2.75%
|
$86,400
$72.14 P/Share
|
|
Jan 31
2023
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
106
-0.28%
|
$34,450
$325.0 P/Share
|
|
Jan 30
2023
|
Lloyd Carney Director |
SELL
Open market or private sale
|
Direct |
2,700
-15.2%
|
$864,000
$320.87 P/Share
|
|
Jan 27
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
1,429
-16.24%
|
$460,138
$322.28 P/Share
|
|
Jan 27
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,429
+30.19%
|
$102,888
$72.14 P/Share
|
|
Jan 26
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
4,000
-17.04%
|
$1,272,000
$318.44 P/Share
|
|
Jan 26
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+40.51%
|
$288,000
$72.14 P/Share
|
|
Jan 25
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
4,000
-29.62%
|
$1,252,000
$313.95 P/Share
|
|
Jan 25
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+40.51%
|
$288,000
$72.14 P/Share
|
|
Jan 25
2023
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
10,000
-10.04%
|
$3,150,000
$315.05 P/Share
|
|
Jan 24
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
4,000
-43.5%
|
$1,248,000
$312.82 P/Share
|
|
Jan 24
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+40.51%
|
$288,000
$72.14 P/Share
|
|
Jan 23
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,129
-53.17%
|
$664,248
$312.02 P/Share
|
|
Jan 23
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,129
+34.71%
|
$153,288
$72.14 P/Share
|
|
Jan 18
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
442
-19.08%
|
$137,904
$312.17 P/Share
|
|
Jan 18
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
442
+16.02%
|
$31,824
$72.14 P/Share
|
|
Jan 17
2023
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
4,000
-68.09%
|
$1,248,000
$312.03 P/Share
|
|
Jan 17
2023
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+40.51%
|
$288,000
$72.14 P/Share
|
|
Dec 06
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
12,753
+18.02%
|
-
|
|
Nov 15
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
34
-0.09%
|
$10,472
$308.61 P/Share
|
|
Nov 07
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,303
-0.51%
|
$394,809
$303.2 P/Share
|
|
Nov 07
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,303
+3.37%
|
$243,661
$187.53 P/Share
|
|
Nov 02
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
320
-0.12%
|
$100,160
$313.56 P/Share
|
|
Nov 01
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
768
-1.96%
|
$239,616
$312.84 P/Share
|
|
Oct 24
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
621
-13.32%
|
$192,510
$310.0 P/Share
|
|
Oct 18
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,791
-2.2%
|
$537,300
$300.93 P/Share
|
|
Sep 19
2022
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,294
+50.0%
|
-
|
|
Aug 15
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,747
-5.22%
|
$1,135,341
$303.14 P/Share
|
|
Aug 15
2022
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
11,689
-10.5%
|
$3,565,145
$305.06 P/Share
|
|
Aug 15
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
22,173
-6.3%
|
$6,718,419
$303.05 P/Share
|